Stay updated on First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.

Latest updates to the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe clinical trial record for first-line tarlatamab combination therapy in extensive-stage small cell lung cancer is available, with details on study design, participation criteria, outcomes, and sites. It also includes the sponsor’s data-sharing plan and related study information.SummaryDifference100%

- Check14 days agoChange DetectedThe ClinicalTrials.gov page remains an error page rather than showing the study record. Its footer now identifies the site revision as v3.8.0.SummaryDifference0.2%

- Check21 days agoChange DetectedA sitewide NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check35 days agoChange DetectedThe site revision shown in the footer changed from v3.7.0 to v3.7.1, while the page remains a 403 error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now shows a 403 Forbidden error, making the study record inaccessible. The content that previously displayed the study details and locations appears to be replaced by the error notice.SummaryDifference21%

Stay in the know with updates to First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.